CN101657464A - 与靶向人源化单克隆抗体复合的多变量抗原 - Google Patents

与靶向人源化单克隆抗体复合的多变量抗原 Download PDF

Info

Publication number
CN101657464A
CN101657464A CN200880010934A CN200880010934A CN101657464A CN 101657464 A CN101657464 A CN 101657464A CN 200880010934 A CN200880010934 A CN 200880010934A CN 200880010934 A CN200880010934 A CN 200880010934A CN 101657464 A CN101657464 A CN 101657464A
Authority
CN
China
Prior art keywords
val
thr
ser
rab
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880010934A
Other languages
English (en)
Chinese (zh)
Inventor
G·祖拉夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of CN101657464A publication Critical patent/CN101657464A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200880010934A 2007-02-02 2008-01-31 与靶向人源化单克隆抗体复合的多变量抗原 Pending CN101657464A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88802907P 2007-02-02 2007-02-02
US60/888,029 2007-02-02

Publications (1)

Publication Number Publication Date
CN101657464A true CN101657464A (zh) 2010-02-24

Family

ID=39682338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880010934A Pending CN101657464A (zh) 2007-02-02 2008-01-31 与靶向人源化单克隆抗体复合的多变量抗原

Country Status (16)

Country Link
US (3) US7786267B2 (enExample)
EP (2) EP2684889A3 (enExample)
JP (1) JP5543785B2 (enExample)
KR (1) KR20090114425A (enExample)
CN (1) CN101657464A (enExample)
AU (1) AU2008214077B2 (enExample)
BR (1) BRPI0807344A2 (enExample)
CA (1) CA2715042C (enExample)
DK (1) DK2114985T3 (enExample)
ES (1) ES2536900T3 (enExample)
IL (1) IL200092A0 (enExample)
MX (1) MX2009008143A (enExample)
NZ (2) NZ592859A (enExample)
TW (1) TW200846371A (enExample)
WO (1) WO2008097817A2 (enExample)
ZA (1) ZA200905447B (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850458A (zh) * 2011-06-28 2013-01-02 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
CN103044552A (zh) * 2012-12-11 2013-04-17 中国医学科学院病原生物学研究所 人源化的抗树突状细胞表面dec-205分子的单克隆抗体
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
CN108064247A (zh) * 2015-02-05 2018-05-22 分子模板公司 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物
CN104364264B (zh) * 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
CN108864291A (zh) * 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
CN110790836A (zh) * 2019-11-22 2020-02-14 郑州安图生物工程股份有限公司 一种人抑制素b的单克隆抗体及其应用和试剂盒
CN111093712A (zh) * 2017-07-06 2020-05-01 国家科学研究中心 缀合度受控的生物缀合物、其制备方法及制备其的试剂

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
KR20090114430A (ko) 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
CN101657464A (zh) * 2007-02-02 2010-02-24 贝勒研究院 与靶向人源化单克隆抗体复合的多变量抗原
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
NZ595319A (en) * 2007-02-23 2012-09-28 Baylor Res Inst Activation of human antigen-presenting cells through clec-6
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
EP2307443B1 (en) * 2008-08-07 2013-10-02 Yeda Research And Development Company Ltd. Affinity purification by cohesin-dockerin interaction
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
DK2406289T3 (en) * 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
US9097713B2 (en) * 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
EP2477655A4 (en) 2009-09-14 2014-02-12 Baylor Res Inst VACCINES TREATED ON LANGERHANS CELLS
BR112012028522A2 (pt) * 2010-05-07 2016-07-19 Baylor Res Inst sensibilização cruzada mediada por imunorreceptores de células dendríticas (dcir) de células t humanas cd8+
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
AR088428A1 (es) * 2011-08-25 2014-06-11 Baylor Res Inst Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
WO2013033104A1 (en) * 2011-08-29 2013-03-07 Baylor Research Institute CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR DECTIN-1 AND TOLL-LIKE RECEPTOR 2 (TLR2)
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
CN105555303A (zh) 2013-06-28 2016-05-04 贝勒研究院 用于多发性硬化症的树突细胞asgpr靶向免疫治疗剂
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
IL263409B2 (en) 2018-12-02 2023-06-01 Linet Spol Sro Detection of tiny movement in the human body
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
MX2022014943A (es) 2020-05-26 2023-03-08 Inst Nat Sante Rech Med Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
MX2023005570A (es) 2020-11-12 2023-05-29 Inst Nat Sante Rech Med Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
EP4267176A1 (en) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
US20240124532A1 (en) 2021-01-29 2024-04-18 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2023088968A1 (en) 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441030A1 (en) * 2001-10-11 2004-07-28 Katakura Industries Co., Ltd. Method of purifying recombinant fused protein and method of producing protein using the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) * 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
AU726108B2 (en) 1995-10-17 2000-11-02 Genencor International, Inc. Enzymatic array and process of making same
FR2748479A1 (fr) * 1996-05-10 1997-11-14 Pasteur Institut Polypeptide comportant un nouveau domaine cohesine de type ii, composition enzymatique en comportant et fragments d'adn codant pour ces polypeptides
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
JP2000157282A (ja) * 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
EP1165813A2 (en) * 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Linear and circular expression elements
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CA2408547A1 (en) * 2000-05-11 2001-11-15 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
JP2004236504A (ja) * 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
US20050064509A1 (en) * 2003-09-23 2005-03-24 The Regents Of The University Of California Use of templated self assembly to create novel multifunctional species
WO2005058244A2 (en) * 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
CN101657464A (zh) * 2007-02-02 2010-02-24 贝勒研究院 与靶向人源化单克隆抗体复合的多变量抗原
KR20090114430A (ko) * 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441030A1 (en) * 2001-10-11 2004-07-28 Katakura Industries Co., Ltd. Method of purifying recombinant fused protein and method of producing protein using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERGEY M DEYEV ET AL: "design of multivalent complexes using the barnase barstar module", 《NATURE BIOTECHNOLOGY》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850458A (zh) * 2011-06-28 2013-01-02 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
CN108864291A (zh) * 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
CN104364264B (zh) * 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
CN103044552A (zh) * 2012-12-11 2013-04-17 中国医学科学院病原生物学研究所 人源化的抗树突状细胞表面dec-205分子的单克隆抗体
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
CN108064247A (zh) * 2015-02-05 2018-05-22 分子模板公司 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物
CN108064247B (zh) * 2015-02-05 2022-06-03 分子模板公司 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物
CN111093712A (zh) * 2017-07-06 2020-05-01 国家科学研究中心 缀合度受控的生物缀合物、其制备方法及制备其的试剂
CN111093712B (zh) * 2017-07-06 2023-12-29 国家科学研究中心 缀合度受控的生物缀合物、其制备方法及制备其的试剂
US11975075B2 (en) 2017-07-06 2024-05-07 Centre National De La Recherche Scientifique Bioconjugates with a controlled degree of conjugation, their process of preparation, and the reagents for their preparation
CN110790836A (zh) * 2019-11-22 2020-02-14 郑州安图生物工程股份有限公司 一种人抑制素b的单克隆抗体及其应用和试剂盒

Also Published As

Publication number Publication date
JP5543785B2 (ja) 2014-07-09
MX2009008143A (es) 2009-10-20
US20100330115A1 (en) 2010-12-30
AU2008214077B2 (en) 2012-12-13
WO2008097817A3 (en) 2008-10-30
NZ578657A (en) 2012-02-24
TW200846371A (en) 2008-12-01
BRPI0807344A2 (pt) 2014-05-20
ES2536900T3 (es) 2015-05-29
CA2715042A1 (en) 2008-08-14
JP2010518020A (ja) 2010-05-27
KR20090114425A (ko) 2009-11-03
CA2715042C (en) 2021-02-02
IL200092A0 (en) 2010-04-15
EP2684889A3 (en) 2014-03-05
EP2684889A2 (en) 2014-01-15
US7786267B2 (en) 2010-08-31
US20160031988A1 (en) 2016-02-04
EP2114985A4 (en) 2010-09-22
AU2008214077A1 (en) 2008-08-14
US20080254044A1 (en) 2008-10-16
NZ592859A (en) 2012-05-25
EP2114985B1 (en) 2014-12-17
WO2008097817A2 (en) 2008-08-14
EP2114985A2 (en) 2009-11-11
DK2114985T3 (en) 2015-03-30
ZA200905447B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
DK2114985T3 (en) Complexes of multivariable antigens and target antibody, a humanized
US12016915B2 (en) Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
EP2129773B1 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
EP2132226B1 (en) Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
CN101668777A (zh) 通过clec-6激活人抗原呈递细胞
AU2012245170B2 (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)
AU2012261626B2 (en) Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
AU2014240262B2 (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)
HK40074322A (en) Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
HK1153501A (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)
HK1135431B (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100224